Sign inJoin waitlistJoin the waitlist

Christopher Striebich

Associate Clinical Director of Clinical Studies · University of Colorado School of Medicine

Credentials: · · · ·

History

Clinical Studies · University of Colorado School of Medicine
Present
University of Colorado School of Medicine
Present

Rheumatology
University of Colorado School of Medicine
1995–1997
Internal Medicine
University of Colorado School of Medicine
1991–1994
University of Texas Medical Branch at Galveston School of Medicine
1987–1991

Research

Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity?
Arthritis & Rheumatism · 2012 · 212 citations
Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus
Annals of the Rheumatic Diseases · 2008 · 177 citations
Selective accumulation of related CD4+ T cell clones in the synovial fluid of patients with rheumatoid arthritis
The Journal of Immunology · 1998 · First of 5 authors · 50 citations

Michael Holers
14 papers
Kevin Deane
13 papers
Kristen Demoruelle
7 papers · 1 as a fellow
James O’Dell
5 papers
Larry Moreland
5 papers
Jane Buckner
4 papers
Maria Danila
4 papers
Gary Firestein
3 papers
Jason Kolfenbach
3 papers
Judith James
3 papers
Kristine Kuhn
3 papers
PG
Peter Gregersen
3 papers

Grants

General Clinical Research Center
National Center for Research Resources · M01
Project lead · $18.2K · University of Colorado Denver
2004–2008

Clinical trials

Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
Study chair · Terminated · Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
2016–2022
Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)
Study chair · Terminated · Phase 1, Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
2006–2009
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
Site PI · Recruiting · Phase 1
GlaxoSmithKline
2024–2028
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2024–2032